

Shom Goel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1595254/publications.pdf>

Version: 2024-02-01

54
papers

6,528
citations

159358

30
h-index

223531

46
g-index

54
all docs

54
docs citations

54
times ranked

11206
citing authors

#	ARTICLE	IF	CITATIONS
1	Normalization of the Vasculature for Treatment of Cancer and Other Diseases. <i>Physiological Reviews</i> , 2011, 91, 1071-1121.	13.1	1,275
2	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017, 548, 471-475.	13.7	998
3	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. <i>Cancer Research</i> , 2013, 73, 2943-2948.	0.4	535
4	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.	7.7	356
5	TGF- β 2 blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16618-16623.	3.3	287
6	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. <i>Trends in Cell Biology</i> , 2018, 28, 911-925.	3.6	273
7	Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006486-a006486.	2.9	266
8	CDK4/6 inhibition in breast cancer: current practice and future directions. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878645.	1.4	218
9	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
10	Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3725-3730.	3.3	169
11	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 763-775.	5.1	144
12	Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3119-27.	3.3	131
13	Targeting CDK4 and CDK6 in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 356-372.	12.8	125
14	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
15	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	106
16	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
17	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	15.2	105
18	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1188-1201.	3.0	101

#	ARTICLE	IF	CITATIONS
19	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. <i>ELife</i> , 2018, 7, .	2.8	91
20	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
21	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
22	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 302-307.	3.3	85
23	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. <i>Cancer Cell</i> , 2017, 31, 576-590.e8.	7.7	84
24	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	7.7	58
25	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. <i>Current Breast Cancer Reports</i> , 2017, 9, 26-33.	0.5	55
26	LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. <i>The Cochrane Library</i> , 2009, , CD004562.	1.5	53
27	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4434-4447.	0.4	52
28	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
29	Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2022, 24, 17.	2.2	45
30	Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1214.	3.3	34
31	Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. <i>JACC: Heart Failure</i> , 2019, 7, 795-804.	1.9	28
32	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	1.1	27
33	Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 276-280.	0.7	25
34	Morphological changes and stress responses in neurons in cerebral cortex infiltrated by diffuse astrocytoma. <i>Neuropathology</i> , 2003, 23, 262-270.	0.7	24
35	Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. <i>The Cochrane Library</i> , 2020, 3, CD013538.	1.5	23
36	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. <i>Translational Oncology</i> , 2021, 14, 100939.	1.7	18

#	ARTICLE	IF	CITATIONS
37	PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. <i>Annals of Oncology</i> , 2016, 27, 1368-1372.	0.6	17
38	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	2.3	17
39	Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1407-1409.	0.8	10
40	Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. <i>Breast</i> , 2011, 20, 101-110.	0.9	9
41	A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1026-1026.	0.8	9
42	Troponin I As a Predictor for Trastuzumab-Related Cardiotoxicity: Current Data Do Not Provide Mechanistic Insights or Allow for Incorporation Into Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, e175-e176.	0.8	8
43	CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?. <i>Lancet Oncology</i> , The, 2019, 20, 1479-1481.	5.1	7
44	CDK4/6 inhibition: the late harvest cycle begins. <i>Oncotarget</i> , 2016, 7, 48854-48856.	0.8	4
45	Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+) Tj ETQq1 1 0.784314 rgBB/Overlo		
46	Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 32-38.	0.7	1
47	Transforming growth factor β^2 in breast cancer: another new trick for the old dog. <i>Immunology and Cell Biology</i> , 2021, 99, 249-251.	1.0	1
48	Cancer drugs in the real world. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 1-3.	0.7	0
49	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 190-202.	0.5	0
50	Adjuvant Chemotherapy in Breast Cancer. , 2015, , 335-351.		0
51	Trastuzumab-related cardiotoxicity: what do we know in 2020?. <i>Translational Cancer Research</i> , 2020, 9, 4052-4055.	0.4	0
52	Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1065-1065.	0.8	0
53	POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. <i>Oncology</i> , 2015, 29, 797-8, 802.	0.4	0
54	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. <i>Cancer Research</i> , 2022, 82, OT2-19-01-OT2-19-01.	0.4	0